BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22983644)

  • 1. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes.
    Bao Y; Jin Y; Chivukula P; Zhang J; Liu Y; Liu J; Clamme JP; Mahato RI; Ng D; Ying W; Wang Y; Yu L
    Pharm Res; 2013 Feb; 30(2):342-51. PubMed ID: 22983644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
    Hashiba K; Sato Y; Harashima H
    J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
    Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
    Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
    Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
    J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
    Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
    Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
    Sato Y; Matsui H; Sato R; Harashima H
    J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.
    Tao W; Davide JP; Cai M; Zhang GJ; South VJ; Matter A; Ng B; Zhang Y; Sepp-Lorenzino L
    Mol Ther; 2010 Sep; 18(9):1657-66. PubMed ID: 20628357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
    Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
    Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
    Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
    J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
    Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
    J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
    Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
    J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery.
    Zhang Y; Arrington L; Boardman D; Davis J; Xu Y; DiFelice K; Stirdivant S; Wang W; Budzik B; Bawiec J; Deng J; Beutner G; Seifried D; Stanton M; Gindy M; Leone A
    J Control Release; 2014 Jan; 174():7-14. PubMed ID: 24240015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.
    Sato Y; Note Y; Maeki M; Kaji N; Baba Y; Tokeshi M; Harashima H
    J Control Release; 2016 May; 229():48-57. PubMed ID: 26995758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
    Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
    ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a Novel PEGylated Liposomal Vector for Systemic Delivery of siRNA to Solid Tumors.
    Song F; Sakurai N; Okamoto A; Koide H; Oku N; Dewa T; Asai T
    Biol Pharm Bull; 2019; 42(6):996-1003. PubMed ID: 31155597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
    Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
    J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.
    Alabi CA; Love KT; Sahay G; Yin H; Luly KM; Langer R; Anderson DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12881-6. PubMed ID: 23882076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.